CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions

Human Immunology

Volumn 71, Issue 10, 2010, Pages 934-941

  Laurent, Stefania ^a   Carrega, Paolo ^b   Saverino, Daniele ^a   Piccioli, Patrizia ^c   Camoriano, Marta ^c   Morabito, Anna ^c   Dozin, Beatrice ^c   Fontana, Vincenzo ^c   Simone, Rita ^a   Mortara, Lorenzo ^d   Mingari, Maria Cristina ^a,c   Ferlazzo, Guido ^e   Pistillo, Maria Pia ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

CTLA 4; Cytokine secretion; DC; T cell proliferation

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; TUBERCULIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MONOCYTES; TUBERCULIN;

EID: 77956610892     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.07.007     Document Type: Article

References (55)

1. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T-cell activation. Immunity 1994, 1:405-413.
2. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997, 7:445-450.
3. Lee K.M., Chuang E., Griffin M., Khattri R., Hong D.K., Zhang W., et al. Molecular basis of T-cell inactivation by CTLA-4. Science 1998, 282:2263-2266.
4. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
5. Merlo A., Tenca C., Fais F., Battini L., Ciccone E., Grossi C.E., Saverino D. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 2005, 12:705-712.
6. Wang X.B., Giscombe R., Yan Z., Heiden T., Xu D., Lefvert A.K. Expression of CTLA-4 by human monocytes. Scand J Immunol 2002, 55:53-60.
7. Kaufman K.A., Bowen J.A., Tsai A.F., Bluestone J.A., Hunt J.S., Ober C. The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 1999, 5:84-87.
8. Nagaraju K., Raben N., Villalba M.L., Danning C., Loeffler L., Lee E., et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999, 92:161-169.
9. Pistillo M.P., Tazzari P.L., Palmisano G.L., Pierri I., Bolognesi A., Ferlito F., et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003, 101:202-209.
10. Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Falà F., Fabbi M., et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005, 117:538-550.
11. Shah K.V., Chien A.J., Yee C., Moon R.T. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 2008, 128:2870-2879.
12. Linsley P.S., Greene J.L., Brady W., Bajorath J., Ledbetter J.A., Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
13. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996, 183:2533-2540.
14. Brunner M.C., Chambers C.A., Chan F.K., Hanke J., Winoto A., Allison J.P. CTLA-4-mediated inhibition of early events of T-cell proliferation. J Immunol 1999, 162:5813-5820.
15. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006, 24:65-97.
16. Blair P.J., Riley J.L., Levine B.L., Lee K.P., Craighead N., Francomano T., et al. CTLA-4 binding delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol 1998, 160:12-15.
17. Alegre M.L., Shiels H., Thompson C.B., Gajewski T.F. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998, 161:3347-3356.
18. Saverino D., Merlo A., Bruno S., Pistoia V., Grossi C.E., Ciccone E. Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J Immunol 2002, 168:207-215.
19. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002, 3:1097-1101.
20. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4:1206-1212.
21. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T-cell proliferation. J Immunol 2000, 164:3596-3599.
22. Taylor P.A., Lees C.J., Fournier S., Allison J.P., Sharpe A.H., Blazar B.R. B7 expression on T cells down-regulates immune responses through CTLA-4 binding via T-T interactions. J Immunol 2004, 172:34-39.
23. Paust S., Lu L., McCarty N., Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 2004, 101:10398-10403.
24. Flores-Borja F., Jury E.C., Mauri C., Ehrenstein M.R. Defects in CTLA-4 are associated with abnormal regulatory T-cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A 2008, 105:19396-19401.
25. Sun T., Zhou Y., Yang M., Hu Z., Tan W., Han X., et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68:7025-7034.
26. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T-cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
27. Lages C.S., Suffia I., Velilla P.A. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 2008, 181:1835-1848.
28. Tenca C., Merlo A., Merck E., Bates E.E., Saverino D., Simone R., et al. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. J Immunol 2005, 174:6757-6763.
29. Leung H.T., Bradshaw J., Cleaveland J.S., Linsley P.S. Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995, 270:25107-25114.
30. Schneider H., Martin M., Agarraberes F.A., Yin L., Rapoport I., Kirchhausen T., Rudd C.E. Cytolytic T lymphocyte-associated antigen-4 and the TCRξ/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol 1999, 163:1868-1879.
31. Taub D.D., Anver M., Oppenheim J.J., Longo D.L., Murphy W.J. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996, 1931-1941.
32. Lane H.C., Anand A.R., Ganju R.K. Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis. Int Immunol 2006, 18:1315-1325.
33. Lanzavecchia A., Sallusto F. Regulation of T-cell immunity by dendritic cells. Cell 2001, 106:263-266.
34. Trinchieri G., Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994, 15:460-463.
35. Moore K.W., O'Garra A., De Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
36. Taylor A., Verhagen J., Akkoç T., Wenig R., Flory E., Blaser K., et al. IL-10 suppresses CD2-mediated T-cell activation via SHP-1. Mol Immunol 2009, 46:622-629.
37. Locati M., Riboldi E., Bonecchi R., Transidico P., Bernasconi S., Haribabu B., et al. Selective induction of phospholipase D1 in pathogen-activated human monocytes. Biochem J 2001, 358:119-125.
38. Valk E., Rudd C.E., Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol 2008, 29:272-279.
39. Mead K.I., Zheng Y., Manzotti C.N., Perry L.C., Liu M.K., Burke F., et al. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J Immunol 2005, 174:4803-4811.
40. De Smedt T., Van Mechelen M., De Becker G., Urbain J., Leo O., Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997, 27:1229-1235.
41. Wang P., Wu P., Siegel M.I., Egan R.W., Billah M.M. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995, 270:9558-9563.
42. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
43. Olsson C., Riesbeck K., Dohlsten M., Michaëlsson E. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T-cell blasts. J Biol Chem 1999, 274:14400-14405.
44. Pioli C., Gatta L., Frasca D., Doria G. Cytotoxic T lymphocyte antigen. 4 (CTLA-4) inhibits CD28-induced IkappaBalpha degradation and RelA activation. Eur J Immunol 1999, 29:856-863.
45. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
46. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174:915-924.
47. Colonna M., Nakajima H., Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 2000, 12:121-127.
48. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002, 3:237-243.
49. Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood 2008, 111:3090-3096.
50. Shi L., Luo K., Xia D., Chen T., Chen G., Jiang Y., et al. DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood 2006, 108:2678-2686.
51. Schneider H., Rudd C.E. Tyrosine phosphatase SHP-2 binding to CTLA-4: Absence of direct YVKM/YFIP motif recognition. Biochem Biophys Res Commun 2000, 269:279-283.
52. Bolland S., Ravetch J.V. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999, 72:149-177.
53. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
54. Ferlazzo G., Semino C., Meta M., Procopio F., Morandi B., Melioli G. T lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties. Eur J Immunol 2002, 32:3092-3101.
55. Newland A., Kireta S., Russ G., Krishnan R. Ovine dendritic cells transduced with an adenoviral CTLA4eEGFP fusion protein construct induce hyporesponsiveness to allostimulation. Immunology 2004, 113:310-317.